OpenAI ( OPENAI ) is reportedly considering drastically lowering the prices it charges users as it seeks to win customers from its rival Anthropic ( ANTHRO ). The company is weighing significant cuts to what it charges for tokens, the unit of measurement artificial-intelligence firms use to bill for their products, WSJ reported, citing sources. The move would be in anticipation of similar cuts the...
OpenAI ( OPENAI ) is reportedly considering drastically lowering the prices it charges users as it seeks to win customers from its rival Anthropic ( ANTHRO ). The company is weighing significant cuts to what it charges for tokens, the unit of measurement artificial-intelligence firms use to bill for their products, WSJ reported, citing sources. The move would be in anticipation of similar cuts the company expects at Anthropic ( ANTHRO ), the people said. The ChatGPT producer currently charges consumers in tiered subscriptions of $8, $20 and $100 and above each month for access to its flagship GPT-5.5 models. Anthropic conversely charges users $17 each month with an annual subscription to Claude Pro, and $100 and above monthly for a subscription to Claude Max. OpenAI on Monday confidentially filed for an initial public offering with the U.S. Securities and Exchange Commission, close on the heels of an IPO filing from Anthropic. More on OpenAI, Anthropic OpenAI: Mega IPO Faces Anthropic Claude Mythos Reckoning Wall Street Lunch: Hot Labor Market Defies Predictions Of AI-Led Job Losses Anthropic: A Strong Buy And Not As Expensive As Many Think Anthropic says government should have right to block risky AI models Trump believes AI companies will be 'giving back' stakes to public
"Bloomberg: The Asia Trade" brings you everything you need to know to get ahead as the trading day begins in Asia. Bloomberg TV is live from Tokyo and Sydney with Shery Ahn and Haidi Stroud-Watts, getting insight and analysis from newsmakers and industry leaders on the biggest stories shaping global markets. (Source: Bloomberg)
"Bloomberg: The Asia Trade" brings you everything you need to know to get ahead as the trading day begins in Asia. Bloomberg TV is live from Tokyo and Sydney with Shery Ahn and Haidi Stroud-Watts, getting insight and analysis from newsmakers and industry leaders on the biggest stories shaping global markets. (Source: Bloomberg)
The European Central Bank is set to raise interest rates for the first time since 2023, judging it can no longer ignore the upswing in inflation caused by the Iran war. With more than three months of fighting keeping oil prices elevated, economists in a Bloomberg poll see the deposit rate being lifted by a quarter point to 2.25%. That would make the ECB the world’s first major central bank to hike...
The European Central Bank is set to raise interest rates for the first time since 2023, judging it can no longer ignore the upswing in inflation caused by the Iran war. With more than three months of fighting keeping oil prices elevated, economists in a Bloomberg poll see the deposit rate being lifted by a quarter point to 2.25%. That would make the ECB the world’s first major central bank to hike in response to the conflict. Like their peers in the US and the UK, euro-zone policymakers have been biding their time in the hope that the latest bout of inflation proves fleeting. But with peace talks making little headway and signs that price gains beyond energy are creeping higher, expectations are building that euro-zone officials will have to tighten more than once this year. New quarterly forecasts will probably suggest inflation, which hit 3.2% in May, is likely to quicken further. Analysts anticipate sharp upward revisions for this year and next, as well as for closely watched underlying pressures. That outlook must be weighed against indications that already meager economic expansion is sagging, however. Surveys pointed to a slump in business activity in May, prompting some to ask how steeply borrowing costs can be increased without sparking a recession. “The ECB is quite clearly tossing up between that and the reality that inflation’s on the rise,” Emma Moriarty , portfolio manager at CG Asset Management Ltd, told Bloomberg Television. “The crisis that’s been going on in the Middle East and the impacts on energy markets are now something that looks much longer than something they can look through.” Follow the ECB TLIV blog here President Christine Lagarde will address that balancing act at a news conference at 2:45 p.m. in Frankfurt, 30 minutes after the ECB’s rate announcement. Interest Rates After Thursday, investors reckon the ECB will hike at least once more this year, bringing rates to the upper end of a range that’s considered to have a neutral impact on t...
Humacyte ( HUMA ) announced the pricing of an underwritten public offering of 47.62M shares of its common stock at a public offering price of $1.05 per share. The gross proceeds from the offering are expected to be approximately $50M, before deducting underwriting discounts, commissions, and other estimated offering expenses. The offering is set to close around June 12, 2026, pending usual conditi...
Humacyte ( HUMA ) announced the pricing of an underwritten public offering of 47.62M shares of its common stock at a public offering price of $1.05 per share. The gross proceeds from the offering are expected to be approximately $50M, before deducting underwriting discounts, commissions, and other estimated offering expenses. The offering is set to close around June 12, 2026, pending usual conditions. Humacyte has also given underwriters the option to purchase an additional 7.14M shares within 30 days at the same price. All shares are being sold by Humacyte itself. Barclays, BTIG, and Titan Partners are the joint book-running managers for this offering. Humacyte intends to use the net proceeds from this offering to fund the commercialization of its Human Acellular Vessel platform under the trade name Symvess®, advance its Biologics License Application for a hemodialysis indication, accelerate broader product pipeline development, and support working capital and general corporate purposes. More on Humacyte Humacyte, Inc. (HUMA) Q1 2026 Earnings Call Transcript Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript Stocks to watch on Wednesday after-hours: ORCL, HUMA, ORGN Humacyte Q1 2026 Earnings Preview